Agalsidase beta Recruiting Phase 3 Trials for Fabry's Disease Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02795676Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function